Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Phase 1b data of QR-010 (PQ-010-002) for Cystic Fibrosis due mid-late 2016

Source Link:: http://www.ir.proqr.com/phoenix.zhtml?c=253704&p=irol-newsArticle&ID=2114567

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

PRQR

Community voting in process

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details Update on the Phase 1b (PQ-010-001) and NPD (PQ-010-002) trials: Patient enrollment continues in Europe and North America for QR-010 for patients with CF associated with the ∆F508 mutation. ProQR is now expecting to release top-line data in mid to late 2016. Patient screening and enrollment is going well, however due to stringent inclusion/exclusion criteria and the recent increase of clinical studies competing for the same patient population, the predicted acceleration of enrollment has not occurred. ProQR is actively implementing recruitment strategies.

http://www.ir.proqr....

Additional Relevant Details Phase 1b preliminary data due at the North American Cystic Fibrosis Conference (NACFC) October 27 - 29, 2016

http://www.ir.proqr....